Medistep Healthcare Ltd IPOMEDISTEP

The IPO opens on 08 Aug 2025 & closes on 12 Aug 2025.

Medistep Healthcare Limited was originally incorporated on June 05, 2023 as a Public Limited Company, pursuant to a Certificate of Incorporation issued by Registrar of Companies, Gujarat. Thereafter, the Company acquired the business of Proprietorship Concern of one of the Promoter Ms. Prajapati Hetalben Girdharilal viz, M/s MG Pharma through the business transfer agreement dated July 02, 2023. Subsequently the business of sole proprietorship firm was transferred into Medistep Healthcare Limited as a going concern. Before the incorporation of Medistep Healthcare Limited, M/s MG Pharma was involved in the business of trading/distribution of pharmaceutical products, intimate care and hygiene products, surgical products, equipment and Nutraceutical products. Medistep Healthcare Limited is a Pharmaceutical Company that has carved a niche in the Healthcare Industry in manufacturing Sanitary pads, Energy powder and trading a diverse range of pharmaceutical products,Nutraceutical products, Intimate Products and surgical products through distribution network. The Company has started manufacturing of sanitary pad and energy powder in January 2024 and is planning an issuance of 37,44,000 Equity Shares of face value of Rs 10/- each through Fresh Issue and Offer for Sale.

Medistep Healthcare Ltd IPO will close on 12 Aug 2025.

<ul><li>Experienced Promoters and Senior Management with extensive domain knowledge.</li><li>Quality assurance and control.</li><li>Market Potential.</li><li>Investment in latest technology and maintain our edge in the market.</li></ul>

<table class="table"> <thead> <tr> <th>S.No</th> <th>Promoters Name</th> <th>Pre Issue Shares</th> <th>Pre Issue Percentage</th> <th>Post Issue Shares</th> <th>Post Issue Percentage</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>Girdhari Lal Prajapat</td> <td>1411800</td> <td>13.49</td> <td>1411800</td> <td>9.94</td> </tr> <tr> <td>2</td> <td>Dabhi Vipul Gobarbhai</td> <td>1269880</td> <td>12.13</td> <td>1269880</td> <td>8.94</td> </tr> <tr> <td>3</td> <td>Prajapati Hetalben Girdharilal</td> <td>7116400</td> <td>68</td> <td>7116400</td> <td>50.08</td> </tr> <tr> <td>4</td> <td>Dabhi dharmishtaben V</td> <td>200</td> <td>---</td> <td>200</td> <td>---</td> </tr> </tbody> </table>

<ul><li>The company provide its goods majorly in Gujarat, any adverse changes in the conditions affecting these regions can adversely affect its business, financial condition and results of operations.</li><li>The company manufacturing facility are subject to operational risks. Any slowdown or shutdown in its manufacturing operations could adversely affect the company business, financial condition and results of operations.</li><li>The company relies on domestic third-party suppliers for the supply of raw materials and any delay, interruption or reduction in such supply could adversely affect its business, results of operations, financial condition and cash flows.</li><li>The company is subject to extensive government regulations and if its fail to obtain, maintain or renew the company statutory and regulatory licenses, permits and approvals required to operate its business, the company business, financial condition, results of operations and cash flows may be adversely affected.</li><li>The Company is dependent on few numbers of customers for sales. The loss of any of this large customer may affect its revenues and profitability.</li><li>Any increase in the cost of its raw material or other purchases or a shortfall in the supply of the company raw materials, may adversely affect the pricing and supply of its products and have an adverse effect on the company business, results of operations and financial condition.</li><li>If the company is unable to patent new processes, obtain trademarks for its products, or protect such proprietary information, the company business may be adversely affected.</li><li>The company inability to accurately forecast demand for its products and manage the company inventory may have an adverse effect on its business, financial condition, results of operations and cash flows.</li><li>The company has had negative cash flows from investing activities during the Financial Year 2024. Negative cash flows over extended periods, or significant negative cash flows in the short term, could affect its ability to operate the company business and implement its growth plans.</li><li>The company requires working capital for its smooth day-to-day operations of business and any discontinuance or its inability to acquire adequate working capital timely and on favourable terms may have an adverse effect on its operations, profitability and growth prospects.</li><li>The Company is yet to place orders for the machinery for the expansion of the business operation. Any delay in placing orders of such machinery may delay the schedule of implementation and possibly increase the cost of commencing operations.</li><li>The property used by the Company for the purpose of its manufacturing, Registered operations is not owned by it. Any termination of the relevant rent agreement in connection with such property or the company failures to renew the same could adversely affect its operations.</li><li>Future success of the company depends on its ability to successfully develop new products and commercialize its products in a timely manner. Any failures to do so could adversely affect its business, results of operations and financial condition.</li><li>The Company is dependent on few suppliers for purchase. Loss of any of these large suppliers may affect its business operations.</li><li>Its may not be able to detect or prevent fraud or other misconduct committed by its employees or third parties.</li><li>The company manufacturing units are subject to quality check requirements which may damage its reputation leading to an adverse effect on its business, results of operations, financial condition and cash flows.</li><li>The company has issued equity shares pursuant to a bonus issue prior to the Issue, and the company will be eligible to issue equity shares pursuant to a bonus issue only when the company has sufficient reserves.</li><li>The Company has issued Equity Shares in the last one year at a price which is lower that the Issue Price.</li><li>The average cost of acquisition of Equity Shares held by its Promoters could be lower than the Issue Price.</li><li>If the company is unable to establish and maintain an effective system of internal controls and compliances, its business and reputation could be adversely affected.</li><li>The Company is dependent on third party transportation providers for the delivery of its goods and any disruption in their operations or a decrease in the quality of their services could affect the Company's reputation and results of operations.</li><li>Its success depends on the company ability to retain and attract qualified senior management and other key personnel, and if its not able to retain them or recruit additional qualified personnel, the company may be unable to successfully develop its business.</li><li>The company relies on daily labour for manufacturing sanitary pads and energy powder, which exposes it to risks such as irregular attendance, fluctuating manpower, and inconsistent skill levels. These factors, may lead to increased costs, operational delays, and adverse effects on its financial performance.</li><li>The company Promoters and the members of its Promoter Group will be able to exercise significant influence and control over it after the Offer and may have interests that are different from or conflicting with those of its other shareholders.</li><li>The company Promoters and certain of its Directors may be involved in ventures which are engaged in the same line of activity or business as that of the Company. Further, its Promoters, certain of the company Directors, Key Managerial Personnel and Senior Management may be interested in the Company other than in terms of remuneration and reimbursement of expenses, and this may result in conflict of interest with the company.</li><li>The company has in the past entered into related- party transactions and may continue to do so in the future.</li><li>Any variation in the utilization of the Net Proceeds would be subject to certain compliance requirements, including prior Shareholders' approval.</li><li>Its funding requirements and proposed deployment of the Net Proceeds of the Offer have not been appraised by a bank or a financial institution or any external agency and if there are any delays or cost overruns, its business, financial condition and results of operations may be adversely affected.</li><li>Information relating to the installed manufacturing capacity, actual production and capacity utilization of its manufacturing facilities included in this Draft Prospectus are based on various assumptions and estimates and future production and capacity may vary.</li><li>Its ability to pay dividends in the future will depends on the company earnings, financial condition, working capital requirements, capital expenditures and restrictive covenants of its financing arrangements.</li><li>The Company, Promoters, and Directors are not involved in certain legal and regulatory proceedings. Any legal matter which may arise in future may have a material adverse effect on its business, financial condition, cash flows and results of operations.</li><li>Delay in raising funds from the IPO could adversely impact the implementation schedule.</li><li>There is no monitoring agency appointed by the Company and the deployment of funds are at the discretion of its Management and the company Board of Directors, though it shall be monitored by its Audit Committee.</li><li>The company insurance coverage may not be sufficient or adequate to cover its losses and liabilities. If the company suffer a large uninsured loss or an insured loss that significantly exceeds its insurance coverage, the company business, results of operations, financial condition and cash flows may be adversely affected.</li><li>The Indian pharmaceutical market is subject to extensive regulation and the company failures to comply with the existing and future regulatory requirements in the pharmaceutical market could adversely affect its business, results of operations and financial condition.</li><li>The company inability to successfully implement its business plan and growth strategy could have an adverse effect on the company business, results of operations, financial condition and cash flows.</li><li>The directors of the company don't have the experience of the listed company and the requirements of being a listed company may strain its resources.</li><li>The Company has file certain forms with delayed fees and company cannot assure that no proceedings or regulatory actions will be initiated against it in relation to the non-filing and delayed filing.</li><li>Delay in making any Statutory payments viz. Tax Deducted at Source, Income Tax, Good and Service Tax, Employee Provident Fund, ESIC or any other Statutory dues which may attract any penalty or demand raised by statutory authorities in future will affect financial position of the Company.</li><li>Expanding a company's business focus from trading pharmaceuticals to manufacturing sanitary pads and energy powders introduces several inherent risk factors that must be carefully evaluated.</li><li>Expanding the company's business focus from trading pharmaceuticals to manufacturing sanitary pads, energy powders, and multivitamins introduces several inherent risk factors that must be carefully evaluated.</li><li>The company provide its goods majorly in Gujarat, any adverse changes in the conditions affecting these regions can adversely affect its business, financial condition and results of operations.</li><li>The company relies on domestic third-party suppliers for the supply of raw materials and any delay, interruption or reduction in such supply could adversely affect its business, results of operations, financial condition and cash flows.</li><li>Its manufacturing facility are subject to operational risks. Any slowdown or shutdown in the company manufacturing operations could adversely affect its business, financial condition and results of operations.</li><li>The Company is dependent on few numbers of customers for sales. The loss of any of this large customer may affect its revenues and profitability.</li><li>The company is subject to extensive government regulations and if its fails to obtain, maintain or renew the company statutory and regulatory licenses, permits and approvals required to operate its business, the company business, financial condition, results of operations and cash flows may be adversely affected.</li><li>Any increase in the cost of its raw material or other purchases or a shortfall in the supply of the company raw materials, may adversely affect the pricing and supply of its products and have an adverse effect on our business, results of operations and financial condition.</li><li>Its inability to successfully implement the company business plan and growth strategy could have an adverse effect on the company business, results of operations, financial condition and cash flows.</li><li>The company has had negative cash flows from investing activities during the Financial Year 2024. Negative cash flows over extended periods, or significant negative cash flows in the short term, could affect its ability to operate the company business and implement its growth plans.</li><li>The company requires working capital for its smooth day-to-day operations of business and any discontinuance or its inability to acquire adequate working capital timely and on favorable terms may have an adverse effect on the company operations, profitability and growth prospects.</li><li>Resignation of its previous Statutory Auditor and appointment of a new Statutory Auditor may affect stakeholders' perception and could raise concerns regarding continuity in financial reporting.</li><li>The Indian pharmaceutical market is subject to extensive regulation and its failures to comply with the existing and future regulatory requirements in the pharmaceutical market could adversely affect our business, results of operations and financial condition.</li><li>Future success of the company depends on its ability to successfully develop new products and commercialize the company products in a timely manner. Any failures to do so could adversely affect its business, results of operations and financial condition.</li><li>The Company is dependent on few suppliers for purchase. Loss of any of these large suppliers may affect its business operation.</li><li>The demand for energy powder is seasonal, Sales are minimal during the rainy and winter seasons, which could impact revenue of company.</li><li>The group Company is engaged in same line of business and there can be conflict of interests of Company.</li><li>Under-Utilization of Our Manufacturing Facility May Adversely Affect its Business, Profitability, and Growth of the Company.</li><li>Its inability to accurately forecast demand for the company products and manage its inventory may have an adverse effect on the company business, financial condition, results of operations and cash flows.</li><li>The Company is yet to place orders for the machinery for the expansion of the business operation. Any delay in placing orders of such machinery may delay the schedule of implementation and possibly increase the cost of commencing operations.</li><li>The property used by the Company for the purpose of its manufacturing, Registered operations is not owned by us. Any termination of the relevant rent agreement in connection with such property or its failures to renew the same could adversely affect the company operations.</li><li>Its may not be able to detect or prevent fraud or other misconduct committed by the company employees or third parties.</li><li>Its manufacturing units are subject to quality check requirements which may damage the company reputation leading to an adverse effect on its business, results of operations, financial condition and cash flows.</li><li>The company relies on daily labour for manufacturing sanitary pads and energy powder, which exposes us to risks such as irregular attendance, fluctuating manpower, and inconsistent skill levels. These factors, may lead to increased costs, operational delays, and adverse effects on its financial performance.</li><li>The company has issued equity shares pursuant to a bonus issue prior to the Issue, and its will be eligible to issue equity shares pursuant to a bonus issue only when the company has sufficient reserves.</li><li>The Company has file certain forms with delayed fees and company cannot assure that no proceedings or regulatory actions will be initiated against it in relation to the non-filing and delayed filing.</li><li>Dependency on particular state for procurement of raw materials could adversely affect its business, results of operations, financial condition.</li><li>The average cost of acquisition of Equity Shares held by its Promoters could be lower than the Issue Price.</li><li>If the company is unable to establish and maintain an effective system of internal controls and compliances, its business and reputation could be adversely affected.</li><li>The Company is dependent on third party transportation providers for the delivery of its goods and any disruption in their operations or a decrease in the quality of their services could affect the Company's reputation and results of operations.</li><li>Its success depends on the company ability to retain and attract qualified senior management and other key personnel, and if the company is not able to retain them or recruit additional qualified personnel, its may be unable to successfully develop the company business.</li><li>Its Promoters and the members of the company Promoter Group will be able to exercise significant influence and control over it after the Offer and may have interests that are different from or conflicting with those of the company other shareholders.</li><li>The company has in the past entered into related-party transactions and may continue to do so in the future.</li><li>Any variation in the utilization of the Net Proceeds would be subject to certain compliance requirements, including prior Shareholders' approval.</li><li>There is no monitoring agency appointed by the Company and the deployment of funds are at the discretion of its Management and the company Board of Directors, though it shall be monitored by its Audit Committee.</li><li>If the company is unable to patent new processes, obtain trademarks for its products, or protect such proprietary information, the company business may be adversely affected.</li><li>Its funding requirements and proposed deployment of the Net Proceeds of the Offer have not been appraised by a bank or a financial institution or any external agency and if there are any delays or cost overruns, its business, financial condition and results of operations may be adversely affected.</li><li>Information relating to the installed manufacturing capacity, actual production and capacity utilization of its manufacturing facilities included in this Prospectus are based on various assumptions and estimates and future production and capacity may vary.</li><li>Its ability to pay dividends in the future will depend on our earnings, financial condition, working capital requirements, capital expenditures and restrictive covenants of its financing arrangements.</li><li>The Company, Promoters, and Directors are not involved in certain legal and regulatory proceedings. Any legal matter which may arise in future may have a material adverse effect on its business, financial condition, cash flows and results of operations.</li><li>Delay in raising funds from the IPO could adversely impact the implementation schedule.</li><li>Its insurance coverage may not be sufficient or adequate to cover the company losses and liabilities. If its suffer a large uninsured loss or an insured loss that significantly exceeds its insurance coverage, the company business, results of operations, financial condition and cash flows may be adversely affected.</li><li>The directors of our company don't have the experience of the listed company and the requirements of being a listed company may strain our resources.</li><li>Delay in making any Statutory payments viz. Tax Deducted at Source, Income Tax, Good and Service Tax, Employee Provident Fund, ESIC or any other Statutory dues which may attract any penalty or demand raised by statutory authorities in future will affect financial position of the Company.</li></ul>

The Issue type of Medistep Healthcare Ltd is Fixed Price - SME.

The minimum application for shares of Medistep Healthcare Ltd is 6000.

The total shares issue of Medistep Healthcare Ltd is 3744000.

Initial public offering of up to 37,44,000 equity shares of Rs. 10/- each ("Equity Shares") of Medistep Healthcare Limited ("the "Company") for cash at a price of Rs. 43/- per equity share (the "Issue Price"), aggregating to Rs. 16.10 crores ("the Offer"). Out of the offer, 1,89,000 equity shares aggregating to Rs. 0.81 crores will be reserved for subscription by market maker ("Market Maker Reservation Portion"). The offer less the market maker reservation portion i.e. offer of 35,55,000 equity shares of face value of Rs. 10.00/- each at an issue price of Rs. 43/- per equity share aggregating to Rs. 15.29 crores is hereinafter referred to as the "Net Offer". The offer and the net offer will constitute 26.35 % and 25.02 %, respectively of the post issue paid up equity share capital of the company. The face value of the equity shares is Rs. 10/- each and the issue price of Rs. 43/- the offer price is 4.3 times of the face value of the equity shares. Bid can be made for a minimum of 2 lot (lot size consist of 3000 equity shares each) and in multiples of 3000 equity shares thereafter.